International Journal of Molecular Sciences,
Journal Year:
2025,
Volume and Issue:
26(3), P. 876 - 876
Published: Jan. 21, 2025
Glioblastoma
is
the
most
common
and
highly
malignant
brain
tumor
in
adults.
New
targeted
therapeutic
approaches
are
imperative.
EGFRvIII
has
appealing
targets
using
monoclonal
antibodies.
Thus,
endeavors
toward
developing
new
mAbs
therapies
for
GBM
capable
of
targeting
biomarker
must
prevail
to
improve
patient’s
prognosis.
Here,
we
isolated
characterized
an
anti-EGFRvIII
vNAR
from
a
non-immune
freshwater
stingray
mixed
library,
termed
R426.
The
R426
pEGFRvIII
interaction
was
demonstrated
by
molecular
docking
dynamics,
recognition
vitro
further
confirmed
cell
immunofluorescence
staining.
Moreover,
shown
be
effective
cisplatin
drug
carrier
U87-MG
glioma
line.
cisplatin-coupled
significant
differences
when
compared
free
CDDP
at
72
h.
Notably,
cisplatin-vNAR
achieved
better
efficacy
described
internalization
receptor-mediated
endocytosis
subsequent
COPI-mediated
nuclear
translocation
highlighted
importance
this
shuttle
mechanism
enhance
delivery
within
cell’s
nucleus
improved
cytotoxic
effect.
In
conclusion,
could
potential
EGFRvIII-targeted
glioblastoma
cancer
therapies.
Cancers,
Journal Year:
2024,
Volume and Issue:
16(8), P. 1485 - 1485
Published: April 12, 2024
Glioblastoma
is
most
commonly
a
primary
brain
tumor
and
the
utmost
malignant
one,
with
survival
rate
of
approximately
12–18
months.
highly
heterogeneous,
demonstrating
that
different
types
cells
from
same
can
manifest
distinct
gene
expression
patterns
biological
behaviors.
Conventional
therapies
such
as
temozolomide,
radiation,
surgery
have
limitations.
As
now,
there
no
cure
for
glioblastoma.
Alternative
treatment
methods
to
eradicate
glioblastoma
are
discussed
in
this
review,
including
targeted
PI3K,
NFKβ,
JAK-STAT,
CK2,
WNT,
NOTCH,
Hedgehog,
TGFβ
pathways.
The
novel
application
oncolytic
viruses
nanomaterials
combating
also
discussed.
Despite
scores
clinical
trials
glioblastoma,
prognosis
remains
poor.
Progress
breaching
blood–brain
barrier
avenues
combination
treatments
hold
promise
future
development
efficacious
therapies.
BJC Reports,
Journal Year:
2024,
Volume and Issue:
2(1)
Published: April 19, 2024
Glioblastoma
(GB)
is
a
lethal
and
aggressive
brain
tumour.
While
molecular
characteristics
of
GB
studied
extensively,
the
aetiology
remains
uncertain.
The
interest
in
exploring
viruses
as
potential
contributor
to
development
stems
from
notion
that
are
known
play
key
role
pathogenesis
other
human
cancers
such
cervical
cancer.
Nevertheless,
controversial.
Small,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 10, 2025
Abstract
Glioblastoma
(GBM),
the
most
malignant
brain
tumor
with
high
prevalence,
remains
highly
resistant
to
existing
immunotherapies
due
significant
immunosuppression
within
microenvironment
(TME),
predominantly
manipulated
by
M2‐phenotypic
tumor‐associated
macrophages
(M2‐TAMs).
Here
in
this
work,
an
M2‐TAMs
targeted
nano‐reprogrammers,
MG5‐S‐IMDQ,
is
established
decorating
mannose
molecule
as
targeting
moiety
well
toll‐like
receptor
(TLR)
7/8
agonist,
imidazoquinoline
(IMDQ)
on
dendrimeric
nanoscaffold.
MG5‐S‐IMDQ
demonstrated
excellent
capacity
of
penetrating
blood‐brain
barrier
(BBB)
selectively
GBM
microenvironment,
leading
a
phenotype
transformation
and
function
restoration
TAMs
shown
heightened
phagocytic
activity
toward
cells,
enhanced
cytotoxic
effects,
improved
antigen
cross‐presentation
capability.
In
meantime,
induction
function‐oriented
“gear
effect”,
treatment
extended
its
impact
systemically
enhancing
infiltration
type
I
conventional
dendritic
cells
(cDC1s)
into
sites
bolstering
adaptive
immune
responses.
sum,
precisely
working
unique
target
situ,
nano‐reprogrammers
successfully
robust
network
that
worked
synergistically
combat
tumors.
This
facile
nanoplatform‐based
immunomodulatory
strategy,
serving
powerful
convenient
monotherapy
or
complementary
alongside
other
therapies
like
surgery,
provided
deep
insights
for
advancing
translational
study
GBM.
International Journal of Molecular Sciences,
Journal Year:
2025,
Volume and Issue:
26(3), P. 876 - 876
Published: Jan. 21, 2025
Glioblastoma
is
the
most
common
and
highly
malignant
brain
tumor
in
adults.
New
targeted
therapeutic
approaches
are
imperative.
EGFRvIII
has
appealing
targets
using
monoclonal
antibodies.
Thus,
endeavors
toward
developing
new
mAbs
therapies
for
GBM
capable
of
targeting
biomarker
must
prevail
to
improve
patient’s
prognosis.
Here,
we
isolated
characterized
an
anti-EGFRvIII
vNAR
from
a
non-immune
freshwater
stingray
mixed
library,
termed
R426.
The
R426
pEGFRvIII
interaction
was
demonstrated
by
molecular
docking
dynamics,
recognition
vitro
further
confirmed
cell
immunofluorescence
staining.
Moreover,
shown
be
effective
cisplatin
drug
carrier
U87-MG
glioma
line.
cisplatin-coupled
significant
differences
when
compared
free
CDDP
at
72
h.
Notably,
cisplatin-vNAR
achieved
better
efficacy
described
internalization
receptor-mediated
endocytosis
subsequent
COPI-mediated
nuclear
translocation
highlighted
importance
this
shuttle
mechanism
enhance
delivery
within
cell’s
nucleus
improved
cytotoxic
effect.
In
conclusion,
could
potential
EGFRvIII-targeted
glioblastoma
cancer
therapies.
